Delta-Fly Pharma,Inc.
4598・Growth Market・Pharmaceuticals
Governance
Company with a Board of Corporate Auditors. The Board of Directors consists of 6 directors (including 3 outside directors, an outside ratio of 50%), and the Board of Corporate Auditors consists of 3 corporate auditors (including 2 outside corporate auditors). The Board of Directors met 18 times during the fiscal year under review, with all directors attending all meetings. No nomination committee or compensation committee has been established.
Risk Management
A system in which each department collects and extracts risk information, and the Board of Directors evaluates the significance of risks along two axes: "likelihood of occurrence" and "degree of financial impact." In the event of unforeseen circumstances, the Company responds in cooperation with external experts such as lawyers, patent attorneys, and certified public accountants.
Shareholder Returns
The company has continued to pay no dividends since its establishment. Because retained earnings carried forward remain negative, it plans to continue not paying dividends for the time being in order to prioritize R&D investment. Future dividend payments will be considered in light of business performance and financial condition.
Dividend Policy
Since retained earnings carried forward are negative, the company has not paid dividends since its establishment. It will continue to prioritize aggressive investment in pharmaceutical R&D and plans to remain dividend-free for the time being. Going forward, it will consider dividend payments in light of business performance and financial condition. When dividends are paid, the basic policy will be a single year-end dividend paid once per year; however, under the Articles of Incorporation, an interim dividend based on the record date of September 30 each year is also possible by resolution of the Board of Directors.
ESG
The Board of Directors oversees sustainability issues. The company has identified "improving the QOL of cancer patients through modular drug discovery" as a materiality issue. On the human capital front, the company conducts diverse mid-career hiring regardless of nationality, age, or gender, has work-life balance systems in place, has developed a telework environment, and conducts regular health checkups and stress checks. At present, no quantitative ESG indicators or targets have been set, and the company is considering whether to establish them going forward.
Last updated: June 24, 2026